@article{8e327535b9a842ea833740dd26da6c08,
title = "Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.",
abstract = "Allogeneic stem cell transplantation (ASCT) is a potentially curative treatment for patients with chronic myelogenous leukemia (CML) and was previously considered the preferred treatment for newly diagnosed CML. The success of imatinib has changed treatment recommendations, and allogeneic transplants are now reserved for imatinib treatment failures. Previous imatinib treatment does not compromise the results of ASCT, but patients with overt transformed disease have poor results. It is unclear whether patients whose disease is considered to have failed imatinib should be referred immediately for ASCT or receive treatment with a second-generation tyrosine kinase inhibitors (TKI). Patients whose disease fails 2 TKIs should receive ASCT if possible. Nonmyeloablative preparative regimens reduce the toxicity and treatment-related mortality associated with the transplantation procedure and allow transplantations to be performed in older and medically infirm patients. This approach, including posttransplantation treatment with TKIs and donor lymphocyte infusion, produces a high fraction of durable molecular complete remissions.",
author = "Richard Champlin and {de Lima}, Marcos and Partow Kebriaei and Gabriela Rondon and Tobi Fisher and Elias Jabbour and Cort{\'e}s, {Jorge E.} and Hagop Kantarjian and Paolo Anderlini and Amin Alousi and Chitra Hosing and Elizabeth Shpall and Uday Popat and Muzaffar Qazilbash and Borje Andersson and Sergio Giralt",
note = "Funding Information: This work was supported by grant CA49639 from the National Cancer Institute and a grant from Genzyme Corporation. Funding Information: Dr. Richard Champlin has received research funding from Genzyme Corporation. Dr. Sirgio Giralt has served on a Speaker{\textquoteright}s Bureau for Celgene Corporation, Millenium Pharmaceuticals, Inc., Ortho Biotech Products, L.P., and has served on an advisory board for Celgene Corporation, Millenium Pharmaceuticals, Inc., and Kyphon. Dr. Uday Popat has served on a Speaker{\textquoteright}s Bureau for and received Honorarium from Novartis Pharmaceuticals Corporation. Dr. Amin Alousi has received research support from Celgene Corporation and THERAKOS, Inc. Dr. Elias Jabbour has served on a Speaker{\textquoteright}s Bureau for Bristol-Myers Squibb Company and Novartis Pharmaceuticals Corporation. Dr. Jorge E. Cort{\'e}s has received research support from Bristol-Myers Squibb Company, ChemGenex Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Wyeth Pharmaceuticals. Dr. Hagop M. Kantarjian has received research support from Bristol-Myers Squibb Company,",
year = "2009",
doi = "10.3816/clm.2009.s.021",
language = "English (US)",
volume = "9 Suppl 3",
pages = "S261--265",
journal = "Clinical lymphoma & myeloma",
issn = "2152-2650",
publisher = "Cancer Media Group",
}